The Seed Investor News Roundup

Biosynthesis: Unlocking the Medical Potential of Cannabis

View the infographic on how Biosynthesis could unlock the full medical potential of Cannabis, unlocking massive market potential.

Read the Investors Guide To Newly Emerging Marijuana Markets

LEARN MORE

Horizons ETFs Expands the Portfolio of its Marijuana-Focused ETF, Adding InMed

InMed's addition to Canada’s Cannabis ETF Could Be Signalling the Start of a Big New Investing Theme = Biotechs.

Canopy Growth and Les Serres Stéphane Bertrand establish joint venture to convert tomato greenhouse for Quebec cannabis production

Canopy Growth Corporation (TSX: WEED) and Canopy Rivers Corporation are pleased to announce a definitive joint venture agreement to form a new company, Les Serres Vert Cannabis Inc., together with Les Serres Stéphane Bertrand Inc., a large-scale tomato greenhouse operator in Mirabel, Quebec.

Supreme Purchases Adjacent Land for Ultra-Premium Cannabis Facility

Supreme Pharmaceuticals Inc. (TSXV:FIRE) is pleased to announce the purchase of an approximately six acre property adjacent to the 7ACRES facility in Kincardine, Ontario. Supreme expects to build an indoor cultivation facility ("Lot 16") to produce high quality, "California-Style" cannabis for the premium product segment.

Aurora Cannabis to File Dissident Circular Against Proposed CanniMed-Newstrike Combination

Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) announced that the Company will be filing a dissident circular, and will be soliciting votes against the resolution of CanniMed Therapeutics Inc. to issue shares in connection with the proposed acquisition of Newstrike Resources Ltd..

Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimerDisclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed investment advisor.

TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260

info@theseedinvestor.com

To keep receiving emails from us, please add us to your address book.